INKEF Capital
Cher Shen Kiar is currently an Associate at Inkef, focusing on portfolio management and due diligence within healthcare and technology investments. Responsibilities include serving as a Board Observer for companies such as Cardior Pharmaceuticals, Salvia Bioelectronics, and Anavo Therapeutics, while also engaging in financial modeling and market analysis. Previously, Cher completed a Wellcome Trust-funded MPhil/PhD at King's College London, specializing in regenerative medicine and cell therapy applications. Other experiences include hands-on research roles at GSK and Nanyang Technological University, internships in business development, and recognition for presentation excellence during academic studies. Cher holds a BSc in Biochemistry from University College London and has advanced degrees in Biomedical Sciences from King's College London.